Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

121. Safety and efficacy of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer (BC): a meta-analysis of randomized controlled trials

Safety and efficacy of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer (BC): a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

122. Risk factors for female breast cancer in Iran: a systematic review and meta-analysis

Risk factors for female breast cancer in Iran: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

123. Taxane-based chemotherapy and risk of breast cancer-related lymphedema: protocol for a systematic review and meta-analysis

Taxane-based chemotherapy and risk of breast cancer-related lymphedema: protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

124. The influence of sarcopenia in breast cancer patients: systematic review and meta-analysis

The influence of sarcopenia in breast cancer patients: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

125. Efficacy and safety of treatments to improve sexual dysfunctions in breast cancer survivors

Efficacy and safety of treatments to improve sexual dysfunctions in breast cancer survivors Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

126. Diagnostic value of serum HER2 level in breast cancer: a systematic review and meta-analysis

Diagnostic value of serum HER2 level in breast cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

127. Breast cancer risk associated with glucagon-like peptide-1 receptor agonist use in patients with type 2 diabetes, prediabetes, obesity and metabolic syndrome: a systematic review

Breast cancer risk associated with glucagon-like peptide-1 receptor agonist use in patients with type 2 diabetes, prediabetes, obesity and metabolic syndrome: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

128. Diagnostic accuracy and clinical utility of axillary ultrasound in invasive breast cancer

Diagnostic accuracy and clinical utility of axillary ultrasound in invasive breast cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

129. Therapies for cognitive impairment in breast cancer survivors treated with chemotherapy: a systematic review and meta-analysis

Therapies for cognitive impairment in breast cancer survivors treated with chemotherapy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

130. The prevalence of factors linked to delayed presentation of breast cancer in Africa: a meta-analysis

The prevalence of factors linked to delayed presentation of breast cancer in Africa: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

131. Prevention of breast and cervical cancer in refugees and asylum seekers: a systematic review and meta-analysis

Prevention of breast and cervical cancer in refugees and asylum seekers: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

132. The association between night shift work and risk of breast and gynecological cancers in female nurses: a systematic review and meta-analysis

The association between night shift work and risk of breast and gynecological cancers in female nurses: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

133. Endocrine therapy versus endocrine therapy plus targeted agents as first line treatment in elderly metastatic breast cancer patients: a systematic review and meta-analysis

Endocrine therapy versus endocrine therapy plus targeted agents as first line treatment in elderly metastatic breast cancer patients: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

134. Efficacy and safety for use of bone modifying agents beyond 2 years of treatment in breast cancer and castration-resistant prostate cancer with bone metastases

Efficacy and safety for use of bone modifying agents beyond 2 years of treatment in breast cancer and castration-resistant prostate cancer with bone metastases Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

135. Impact of full field digital mammography (FFDM) diagnosis for patients with breast cancer (BC): a systematic review protocol of clinical studies

Impact of full field digital mammography (FFDM) diagnosis for patients with breast cancer (BC): a systematic review protocol of clinical studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

136. A systematic review and meta-analysis of the distress thermometer for screening distress in patients with breast cancer

A systematic review and meta-analysis of the distress thermometer for screening distress in patients with breast cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

137. Adult weight gain and the risk of postmenopausal breast cancer in Asian women: a dose-response meta-analysis

Adult weight gain and the risk of postmenopausal breast cancer in Asian women: a dose-response meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

138. A systematic review of weekly cisplatin for treating patients with breast cancer

A systematic review of weekly cisplatin for treating patients with breast cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

139. Association between breast density and breast cancer risk in Asian women

Association between breast density and breast cancer risk in Asian women Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

140. Breast cancer patients' experiences of mindfulness-based stress reduction (MBSR): a qualitative systematic review

Breast cancer patients' experiences of mindfulness-based stress reduction (MBSR): a qualitative systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO